Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

26 Sept 2019

Abstract excerpt

Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available. Published studies using the VENTANA PD-L1 (SP263) Assay, VENTANA PD-L1 (SP142) Assay, Dako PD-L1 IHC 22C3 pharmDx assay, Dako PD-L1 IHC 28-8 pharmDx assay, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31558782
DOI: 10.1038/s41379-019-0372-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesPMID 31558782Read ↗

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue TypesSemantic proximity Read ↗

A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.Semantic proximity Read ↗

Antibodies for profiling the human proteome—The <scp>H</scp>uman <scp>P</scp>rotein <scp>A</scp>tlas as a resource for cancer researchSemantic proximity Read ↗

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.Semantic proximity Read ↗

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.Semantic proximity Read ↗

Characterization of a new anti-LAG3 monoclonal for immuno-oncologySemantic proximity Read ↗

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithmsSemantic proximity Read ↗

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platformsSemantic proximity Read ↗

Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplaySemantic proximity Read ↗

Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison studySemantic proximity Read ↗

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discoverySemantic proximity Read ↗

High-Resolution Epitope Mapping and Affinity Binding Analysis Comparing a New Anti-Human LAG3 Rabbit Antibody Clone to the Commonly Used Mouse 17B4 CloneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.